Phase II AK Study in Organ Transplant Patients
A Multicentre, Randomised, Double-Blind, Placebo Controlled, Phase II Study to Evaluate the Safety and Efficacy of Subcutaneous Bioresorbable Implants of Afamelanotide (CUV1647) for the Prophylactic Treatment of Pre-Cancerous Skin Lesions of the Head, Forearms and Hands in Immune Compromised, Organ Transplant Patients.
Sponsor: Clinuvel Pharmaceuticals Limited
A PHASE2 clinical study on Actinic Keratoses and Carcinoma, Squamous Cell, this trial is ongoing. The trial is conducted by Clinuvel Pharmaceuticals Limited and has accumulated 6 data snapshots since 2007. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Unknown PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Unknown Status PHASE2
▶ Show 1 earlier version
-
Jan 2017 — Jun 2018 [monthly]
Unknown Status PHASE2
First recorded
Nov 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Clinuvel Pharmaceuticals Limited
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Adelaide, Australia , Bergamo, Italy , Berlin, Germany , Besançon, France , Brisbane, Australia , Brussels, Belgium , Ghent, Belgium , Kiel, Germany , Melbourne, Australia , Padua, Italy and 2 more locations